A Phase 2 Study of XL184 in Subjects With Progressive or Recurrent Glioblastoma Multiforme in First or Second Relapse.
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Exelixis
- 27 Jun 2017 Converging evidence from 5 seperate phase II trials (NCT00035656, NCT00345163, NCT00704288, NCT00369590 and NTR1929) results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 15 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Feb 2013 Planned end date changed from 1 Dec 2011 to 1 May 2013 as reported by ClinicalTrials.gov.